This study aims to develop the population pharmacokinetic model of ritonavir-boosted atazanavir in Thai HIV-infected patients. The population mean pharmacokinetic parameters and their interindividual variability will be estimated. Moreover, the influence of patient characteristics including age, weight, laboratory tests for hepatic function, and co-medications on the pharmacokinetic parameters of atazanavir will be identified and quantified. Additionally, the model obtained from the population pharmacokinetic analysis will be used to determine the optimal dose of ritonavir-boosted atazanavir that provides the concentrations in the optimal range.
